Research Topics
| D L HeymannSummaryAffiliation: World Health Organization Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Smallpox containment updated: considerations for the 21st centuryDavid L Heymann
Polio Eradication, World Health Organization, 1211 Geneva 27, Switzerland
Int J Infect Dis 8:S15-20. 2004....- Poliomyelitis eradication and pandemic influenzaDavid L Heymann
Polio Eradication Initiative, World Health Organization, Geneva 27, Switzerland
Lancet 367:1462-4. 2006 - Resistance to anti-infective drugs and the threat to public healthDavid L Heymann
World Health Organization, Geneva 27 1211, Switzerland
Cell 124:671-5. 2006..Increasing resistance of pathogens to anti-infective drugs is an urgent public health problem that must be addressed through more prudent use of these drugs in human medicine and in animal husbandry, agriculture, and aquaculture... - Social, behavioural and environmental factors and their impact on infectious disease outbreaksDavid L Heymann
World Health Organization, Switzerland
J Public Health Policy 26:133-9. 2005.... - A vision of a world without polio: the OPV cessation strategyDavid L Heymann
World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
Biologicals 34:75-9. 2006..Final preparations for the eventual global and simultaneous cessation of OPV will require the same level of international cooperation and coordination that has brought the world to the verge of polio eradication... - From smallpox to polio and beyond: disease surveillance in IndiaDavid L Heymann
World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
Indian J Med Res 120:70-2. 2004 - The international response to the outbreak of SARS in 2003David L Heymann
World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
Philos Trans R Soc Lond B Biol Sci 359:1127-9. 2004.... - Dangerous pathogens in the laboratory: from smallpox to today's SARS setbacks and tomorrow's polio-free worldDavid L Heymann
Polio Eradication InitiativeWHO, Geneva 1211, Switzerland
Lancet 363:1566-8. 2004 - Global surveillance, national surveillance, and SARSDavid L Heymann
World Health Organization, Geneva, Switzerland
Emerg Infect Dis 10:173-5. 2004 - Mass vaccination: when and whyD L Heymann
World Health Organization, Geneva, Switzerland
Curr Top Microbiol Immunol 304:1-16. 2006..In the twenty-first century, mass vaccination and routine immunization remain a necessary alliance for attaining both national and international goals in the control of vaccine preventable disease... - Hot spots in a wired world: WHO surveillance of emerging and re-emerging infectious diseasesD L Heymann
World Health Organization, Communicable Disease Programmes, Geneva, Switzerland
Lancet Infect Dis 1:345-53. 2001..About 65% of the world's first news about infectious disease events now comes from informal sources, including press reports and the internet... - Ebola hemorrhagic fever: lessons from Kikwit, Democratic Republic of the CongoD L Heymann
Division of Emerging and Other Communicable Diseases, World Health Organization WHO, Geneva, Switzerland
J Infect Dis 179:S283-6. 1999..Finally, a need for continued and coordinated Ebola research was identified, especially as concerns development of simple and valid diagnostic tests, better patient management procedures, and identification of the natural reservoir... - Rumors of disease in the global village: outbreak verificationT W Grein
Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva, Switzerland
Emerg Infect Dis 6:97-102. 2000..We describe the context and processes of outbreak verification and information dissemination... - SARS and emerging infectious diseases: a challenge to place global solidarity above national sovereigntyDavid L Heymann
World Health Organization, Geneva, Switzerland
Ann Acad Med Singapore 35:350-3. 2006.... - Policy. OPV cessation--the final step to a "polio-free" worldR Bruce Aylward
Global Polio Eradication Initiative, World Health Organization, Geneva 27 Switzerland
Science 310:625-6. 2005..This Policy Forum reviews the feasibility and implications of eventually stopping the use of live polio vaccines... - A global call for new polio vaccinesDavid L Heymann
Global Polio Eradication Initiative, World Health Organization, 20 Avenue Appia, CH-1211 Geneva, Switzerland
Nature 434:699-700. 2005 - Communicable diseases in complex emergencies: impact and challengesMaire A Connolly
World Health Organization, Geneva, Switzerland
Lancet 364:1974-83. 2004..In addition, further research is needed to adapt and simplify interventions, and to explore novel diagnostics, vaccines, and therapies... - Global public health securityGuenael Rodier
World Health Organization, Geneva, Switzerland
Emerg Infect Dis 13:1447-52. 2007..The new International Association of National Public Health Institutes aims to strengthen and invigorate existing NPHIs, to create new NPHIs where none exist, and to provide funded grants to support NPHI development priorities... - Can we capitalize on the virtues of vaccines? Insights from the polio eradication initiativeR Bruce Aylward
Polio Eradication Initiative, World Health Organization, 20, Avenue Appia, CH 1211 Geneva 27, Switzerland
Am J Public Health 95:773-7. 2005.... - Eradicating polioDavid L Heymann
Polio Eradication Initiative, World Health Organization, Geneva
N Engl J Med 351:1275-7. 2004 - A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979-1980. Ebola Virus Study TeamsJ G Breman
Smallpox Eradication Unit, World Health Organization, Geneva, Switzerland
J Infect Dis 179:S139-47. 1999..This study was limited in time and animal collections and excluded insects and plants. Long-term, prospective, multidisciplinary comparative studies will yield more information than will repeat short forays on the ecology of filoviruses... - Control, elimination, eradication and re-emergence of infectious diseases: getting the message rightDavid L Heymann
Bull World Health Organ 84:82. 2006 - The microbial threat in fragile times: balancing known and unknown risksDavid L Heymann
Bull World Health Organ 80:179. 2002 - Microbes and humans: the long danceAdrian K Ong
Bull World Health Organ 85:422. 2007 - Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control studyNicholas C Grassly
Department of Infectious Disease Epidemiology, Imperial College London, London, UK
Lancet 369:1356-62. 2007..A high-potency monovalent oral type 1 poliovirus vaccine (mOPV1) was developed in 2005 to tackle persistent poliovirus transmission in the last remaining infected countries. Our aim was to assess the efficacy of this vaccine in India... - New strategies for the elimination of polio from IndiaNicholas C Grassly
Department of Infectious Disease Epidemiology, Imperial College London, Norfolk Place, London, UK
Science 314:1150-3. 2006..We analyze strategies to counteract this and show that switching to monovalent vaccine may finally interrupt virus transmission... - Interview with David L. Heymann, MD, representative for polio eradication and former Executive Director, Communicable Diseases, World Health Organization. Interview by Madeline DrexlerDavid L Heymann
Biosecur Bioterror 1:233-7. 2003 - Polio eradication: finishing the job and protecting the investmentDavid L Heymann
Bull World Health Organ 82:1. 2004 - India holds key to polio-free worldDavid L Heymann
J Indian Med Assoc 103:654. 2005 - The polio eradication endgame. As polio eradication nears realization, such real-world vaccination strategies could hold lessons for the future in AIDS vaccine developmentDavid L Heymann
IAVI Rep 10:13-7. 2006 - World Health Assembly 2008: climate change and healthAnthony J McMichael
Australian National University, Canberra, ACT 0200, Australia
Lancet 371:1895-6. 2008 - NPHIs as focal points for leadership in prevention and control of infectious diseasesDavid L Heymann
J Public Health Policy 29:374-6. 2008